Newcastle University, Newcastle,
Professor Quentin Anstee is the Chair of Experimental Hepatology and the Deputy-Dean of Research & Innovation in the Faculty of Medical Sciences, Newcastle University, Newcastle, UK. A practising clinician, he is also an Honorary Consultant Hepatologist in the Liver Transplant Unit at Newcastle’s Freeman Hospital, where he leads one of the largest non-alcoholic fatty liver disease (NAFLD) clinical services in the UK. He trained in medicine at University College London, London, UK, where he was awarded a first-class honours degree and won First Prize in Medicine in the final MB BS examination.
Professor Anstee’s translational research has made major contributions across the pathophysiology, natural history,t diagnosis and treatment of NAFLD. His work has provided key insights into temporal changes in steatohepatitis during disease evolution, identified genetic and epigenetic modifiers of liver disease progression and hepatocellular carcinoma risk, and has substantially advanced the field of biomarker development in liver disease. Professor Anstee coordinates two major international research consortia that are studying NAFLD pathogenesis and developing/validating accurate biomarkers to assist the diagnosis, risk-stratification and monitoring of patients with NAFLD: ‘EPoS’ Elucidating Pathways of Steatohepatitis (EU H2020 funded €6 million, 2015–2019) and ‘LITMUS’ Liver Investigation: Testing Marker Utility in Steatohepatitis (EU IMI2 funded €47.3 million, 2017–2023). He leads the European NAFLD Registry and is the chief investigator of multiple ongoing clinical trials assessing new medical therapies for NAFLD. Professor Anstee is an Associate Editor of the Journal of Hepatology.